• 不 限
  • 期刊论文
  • 硕博论文
  • 会议论文
  • 报 纸
  • 英文论文
  2. 您的位置
  3. 首页
  4. 会议论文
  5. Population Pharmacokinetic/Pharmacodynamic Model for C.E.R.A.in Both ESA-Na(i)ve and ESA-Treated Chr

Population Pharmacokinetic/Pharmacodynamic Model for C.E.R.A.in Both ESA-Na(i)ve and ESA-Treated Chr

来源 :2013年中国肾性贫血治疗专家共识研讨会 | 被引量 : 0次 | 上传用户：ztlzp
【摘 要】
：
This study aimed to develop a population pharmacokinetic/pharrnacodynamic (PK/PD) model for C.E.R.A., a continuous erythropoietin receptor activator.C.E.R.A.is administered via intravenous (Ⅳ) and sub
【作 者】
：
Pascal Chanu Ronald Gieschke Jean-Eric Charoin Anne Pannier Bruno Reigner 
【机 构】
：
Pharsight-A Certara Company,Lyon, France Pharma D
【出 处】
：
2013年中国肾性贫血治疗专家共识研讨会
【发表日期】
：
2012年12期
【关键词】
：
modeling simulation C.E.R.A. pharmacokinetics pharmacodynamics 
下载到本地 , 更方便阅读
下载此文 赞助VIP
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
This study aimed to develop a population pharmacokinetic/pharrnacodynamic (PK/PD) model for C.E.R.A., a continuous erythropoietin receptor activator.C.E.R.A.is administered via intravenous (Ⅳ) and subcutaneous (SC) routes once every 2 weeks (Q2W) or once every 4 weeks (Q4W), respectively, to correct or maintain hemoglobin levels in chronic kidney disease (CKD) patients.
其他文献
Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia
BACKGROUND Whether correction of anemia in patients with stage 3 or 4 chronic kidney disease improves cardiovascular outcomes is not established.METHODS We randomly assigned 603 patients with an estim
会议
Associations between Changes in Hemoglobin and Administered Erythropoiesis-Stimulating Agent and Sur
AlthOugh treating anemia of chronic kidney disease by erythropoiesis-stimulating agents (ESA) may improve survival, most studies have examined associations between baseline hemoglobin values and survi
会议
Double-Blind Comparison of Full and Partial Anemia Correction in Incident Hemodialysis Patients with
It is unclear whether physiologic hemoglobin targets lead to cardiac benefit in incident hemodialysis patients without symptomatic heart disease and left ventricular dilation.In this randomized, doubl
会议
Erythropoietin Therapy, Hemoglobin Targets, and Quality of Life in Healthy Hemodialysis Patients: A
Background and objectives: The effects of different hemoglobin targets when using erythropoiesis-stimulating agents on quality of life are somewhat controversial, and predictors of change in quality o
会议
Current and Upcoming Erythropoiesis-Stimulating Agents, Iron Products, and Other Novel Anemia Medica
Treatment for anemia has come a long way in the last 20 years since the first recombinant human erythropoietins were licensed for the management of anemia in chronic kidney disease.The first-generatio
会议
AnemiaRenalESAsErythropoietinEpoetinIron
Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties
Epoetin alfa and beta are the two forms of recombinant DNA-derived erythropoietin (rEPO), both synthesized in Chinese hamster ovary cells, which are used for the treatment of erythropoietin (EPO)-resp
会议
epoetin alfaepoetin betaerythropoietin isoformslectin-bindingbiological prop
Comparison of the Therapeutic Efficacy of Epoetin Beta and Epoetin Alfa in Maintenance Phase Hemodia
In May 2009 for financial reasons, the epoetin product used for hemoglobin (Hb) maintenance in our renal dialysis unit was changed from epoetin beta to epoetin alfa.Although widely believed that the d
会议
Hemodialysisanemiaepoetin alfaepoetin beta
Pain at the injection site of subcutaneously administered erythropoietin:phosphate-buffered epoetin
Patients may complain of pain at the injection site after subcutaneous (s.c.) administration of erythropoietin (EPO).Local pain due to s.c.EPO into the thigh was evaluated in 60 hemodialysis patients
会议
erythropoietinsubcutaneouspain
The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin results fro
Background.Anaemia in haemodialysis patients can be effectively treated with erythropoietin.We investigated whether subcutaneous (SC) epoetin β administered once weekly was as effective as the same we
会议
epoetin betarenal anaemiasubcutaneous
An erythropoiesis-stimulating agent for the treatment of anemia in patients with chronic kidney dise
Chronic kidney disease (CKD) affects 20 million Americans, and an additional 20 million are at increased risk for developing CKD.Anemia is a common complication in patients with CKD.The predominant ca
会议